--- title: "Metastasis‑directed radiotherapy (MDRT) for de novo oligometastatic prostate cancer: METANOVA phas" id: "bmj-open-0-metastasis-directed-radiotherapy-mdrt-for-men-with-de-novo-oligometastatic" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-0-metastasis-directed-radiotherapy-mdrt-for-men-with-de-novo-oligometastatic" content_type: "clinical_feed_article" specialty: "Oncology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/10/e116331?rss=1" published_at: "2026-10-06T11:59:03.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Metastasis‑directed radiotherapy (MDRT) for de novo oligometastatic prostate cancer: METANOVA phas ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-0-metastasis-directed-radiotherapy-mdrt-for-men-with-de-novo-oligometastatic - **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/10/e116331?rss=1) - **Published At:** 2026-10-06T11:59:03.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - The METANOVA protocol describes a multicentre, randomised phase II trial evaluating **metastasis-directed radiotherapy (MDRT)** in men with de novo oligometastatic, hormone-sensitive prostate cancer (omHSPC). - Eligibility permits up to 10 metastatic sites by **PSMA PET/CT** or up to five sites by conventional imaging. Patients receive long-term androgen deprivation therapy plus an androgen receptor pathway inhibitor and definitive prostate treatment as standard of care (SOC). - Participants are randomised 1:1 to SOC alone versus SOC plus MDRT; target enrolment is 200 patients with stratification by imaging modality, number of bone metastases, plan to treat all metastatic sites, and local therapy approach. - MDRT uses **stereotactic body radiation therapy (SBRT)** to all metastatic lesions, aiming for a biologically effective dose ≥100 Gy (α/β=1.5) delivered in 1–5 fractions. Prostate RT options include moderate hypofractionation (20 fractions) or ultra‑hypofractionation (five fractions), with optional simultaneous-integrated-boost to dominant intraprostatic lesions. - Gross tumour volumes are delineated from MRI, CT and **PSMA PET/CT**. A predefined subset may undergo radical prostatectomy instead of RT when appropriate. - The primary endpoint is **failure-free survival**, defined using cause-specific prostate cancer death. The trial is powered at 80% to detect a hazard ratio of 0.58 with a one-sided alpha of 0.05. - Secondary endpoints include radiographic progression-free survival, overall survival, time to next intervention, time to castration-resistant prostate cancer, prostate cancer-specific mortality and patient-reported outcomes. - Biospecimens and imaging datasets are collected for planned translational research. Data are preplanned to be pooled with the STAMPEDE 2 phase III trial. Ethical approval was obtained from the Case Comprehensive Cancer Center IRB. Trial registration: NCT06150417. ## Clinical Analysis & Structured Key Points Introduction Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic disease, defined by a limited number of metastases, which may represent a distinct clinical entity with potential for long-term disease control. Emerging evidence suggests that metastasis-directed radiotherapy (MDRT), including stereotactic body radiation therapy (SBRT), may improve progression-free survival in this population. However, current evidence is largely limited to phase II trials in the metachronous setting and retrospective studies in the synchronous setting. Furthermore, predictive biomarkers of treatment response in these patients remain undefined. We aim to evaluate, within a large randomised multicentre phase II trial, the efficacy and biological impact of MDRT in men with de novo oligometastatic PCa. Methods and analysis Patients with de novo oligometastatic hormone-sensitive prostate cancer (omHSPC), defined as up to 10 sites of metastatic disease by prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT or up to five sites of metastatic disease by conventional imaging, are randomised (1:1) to standard of care (SOC) or SOC plus MDRT. SOC includes 12 months of androgen deprivation therapy plus an androgen receptor pathway inhibitor, with definitive treatment to the prostate by radiotherapy (RT). A predefined subset is allowed to undergo radical prostatectomy if clinically appropriate. MDRT involves SBRT to all metastatic sites identified on conventional imaging or PSMA PET/CT. Target enrolment is 200 patients, stratified by diagnostic imaging modality, number of bone metastases, plan to MDRT all sites of metastases and local therapy approach. Prostate RT may be delivered using moderate (20 fractions) or ultra-hypofractionation (five fractions), with optional simultaneous-integrated-boost to dominant intraprostatic lesions. MDRT regimens aim for a biologically effective dose ≥100 Gy (α/β=1.5) using 1 - 5 fractions. Gross tumour volumes are delineated based on MRI, CT and PSMA PET/CT. The primary endpoint is failure-free survival, defined using cause-specific PCa death. The study is powered at 80% to detect a HR of 0.58 using a one-sided alpha of 0.05. Secondary endpoints include radiographic progression-free survival, overall survival (OS), time to next intervention, time to castration-resistant PCa, PCa-specific mortality and patient-reported outcomes. Biospecimen collection and imaging data will support future translational analyses. Data from this trial is preplanned to be pooled with the STAMPEDE 2 (NCT06320067) trial, a phase III randomised trial to assess OS benefit of MDRT in men with de novo omHSPC. Ethics and dissemination This clinical trial is approved by the Case Comprehensive Cancer Center Institutional Review Board (STUDY20231440). The results will be disseminated via peer-reviewed scientific journals and conference presentations. Trial registration number NCT06150417 ( https://clinicaltrials.gov/study/NCT06150417 ) ## Related Clinical Research - [Editorial Expression of Concern: Image concerns in EphA2–arachidonic acid prostate cancer paper](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-editorial-expression-of-concern-ligand-independent-activation-of-epha2-by.md) - [Cribriform on Follow-up Biopsy Predicts Active Surveillance Failure in MRI-Era Prostate Cancer](https://medichelpline.com/clinical-feed/medrxiv-21-cribriform-status-at-follow-up-biopsy-is-critical-for-predicting-prostate.md) - [Galleri multicancer blood test: expert views on performance, limits, and clinical use](https://medichelpline.com/clinical-feed/healthcare-dive-2-5-doctors-weigh-in-on-the-promise-limitations-of-a-closely-watched-multicancer.md) - [SRSF1 controls transcription and alternative splicing to alter p53 signaling and genome maintenance](https://medichelpline.com/clinical-feed/biorxiv-4-srsf1-coordinates-transcription-and-alternative-splicing-to-modulate-p53-and.md) - [Immune biomarkers linked to response and resistance with ipilimumab plus nivolumab in mCRPC](https://medichelpline.com/clinical-feed/pubmed-42873849.md) (DOI: 10.1126/sciadv.aee8730) ## Navigation - [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.